Two sets of 10-year outcome data from large multicenter trials with checkpoint inhibitors for the treatment of advanced melanoma found that more than 40% of treated patients survive 10 years overall, but the 10-year melanoma-free survival approaches 100% in those with a deep response who remain in progression-free survival (PFS) at three years.
Conferences
ESMO: Merck’s Keytruda tames stage 2 melanoma, reducing cancer recurrence in postsurgery use
Stage 3 melanoma was the first cancer area to have an FDA-approved immunotherapy to prevent disease from returning after surgery.
ESMO announces award winners
The European Society for Medical Oncology announced the recipients of this year’s ESMO Awards.
For cancer treatment and more, genetic-based precision medicine holds a lot of promise
A month following surgery for thyroid cancer, a Hartford Hospital patient’s tumor grew to 10 inches. The case was presented to the hospital’s tumor board, which involved 30 doctors from different specialties.